CACNA1E

Chr 1AD

calcium voltage-gated channel subunit alpha1 E

Also known as: BII, CACH6, CACNL1A6, Cav2.3, DEE69, EIEE69, gm139

The protein forms the alpha-1E subunit of R-type voltage-dependent calcium channels that mediate calcium entry into excitable cells and modulate neuronal firing patterns important for information processing. Mutations cause developmental and epileptic encephalopathy 69 with autosomal dominant inheritance. The gene is highly constrained against loss-of-function variants, and mutations can cause disease through multiple mechanisms depending on the specific variant type.

OMIMResearchSummary from RefSeq, OMIM, UniProt
GOFmechanismADLOEUF 0.121 OMIM phenotype
Clinical SummaryCACNA1E
🧬
Gene-Disease Validity (ClinGen)
developmental and epileptic encephalopathy · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint
0.12LOEUF
pLI 1.000
Z-score 9.29
OE 0.07 (0.040.12)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint
5.81Z-score
OE missense 0.56 (0.520.59)
750 obs / 1351.3 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios
LoF OE0.07 (0.040.12)
00.351.4
Missense OE0.56 (0.520.59)
00.61.4
Synonymous OE1.01
01.21.6
LoF obs/exp: 8 / 115.9Missense obs/exp: 750 / 1351.3Syn Z: -0.21
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongCACNA1E-related epileptic encephalopathy with contractures, macrocephaly, and dyskinesiaGOFAD
Mechanism Note (expert annotation)
GOF

Cav2.3 alpha subunit is monomeric at the pore level. DEE69 variants cause GOF with increased calcium influx and shifted voltage dependence.

References:PMID:30531870
DN
0.5378th %ile
GOF
0.6833th %ile
LOF
0.61top 25%

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 1 literature citation
LOFLOEUF 0.12

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFThere were several recurrent mutations. In vitro functional expression studies of some of the mutations in human tsA201 transformed kidney cells showed that they resulted in consistent gain-of-function effects, including facilitated voltage-dependent channel activation, slowed inactivation, and incrPMID:30343943

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CACNA1E · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →